Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: A multidatabase cohort study

Annals of the Rheumatic Diseases

Volumn 78, Issue 4, 2019, Pages 456-464

  Pawar, Ajinkya ^a   Desai, Rishi J ^a   Solomon, Daniel H ^a   Santiago Ortiz, Adrian J ^a   Gale, Sara ^b   Bao, Min ^b   Sarsour, Khaled ^b   Schneeweiss, Sebastian ^a   Kim, Seoyoung C ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b GENENTECH INC   (United States)

Author keywords

abatacept; bacterial infections; biologic therapy; rheumatoid arthritis; serious infections; tocilizumab; tumor necrosis factor inhibitor

Indexed keywords

ABATACEPT; ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; TOCILIZUMAB; TOFACITINIB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BACTEREMIA; BACTERIAL INFECTION; CLINICAL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; DATA ANALYSIS; DATA BASE; DISEASE SEVERITY; DIVERTICULITIS; FEMALE; HAZARD RATIO; HOSPITALIZATION; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MEDICARE; OPPORTUNISTIC INFECTION; PNEUMONIA; POPULATION RESEARCH; PRIORITY JOURNAL; PROPENSITY SCORE; RHEUMATOID ARTHRITIS; SEPTICEMIA; SKIN INFECTION; SOFT TISSUE INFECTION; TREATMENT OUTCOME; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION; CLINICAL TRIAL; COMORBIDITY; FACTUAL DATABASE; MIDDLE AGED; MULTICENTER STUDY; PROCEDURES; RISK ASSESSMENT;

ABATACEPT; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BACTERIAL INFECTIONS; BIOLOGICAL PRODUCTS; COHORT STUDIES; COMORBIDITY; DATABASES, FACTUAL; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; RISK ASSESSMENT; TUMOR NECROSIS FACTOR INHIBITORS; UNITED STATES; VIRUS DISEASES;

EID: 85060626751     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2018-214367     Document Type: Article

References (38)

1. Au K, Reed G, Curtis JR, et al. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis 2011;70:785-91.
2. Michaud TL, Rho YH, Shamliyan T, et al. The comparative safety of tumor necrosis factor inhibitors in rheumatoid arthritis: A meta-analysis update of 44 trials. Am J Med 2014;127:1208-32.
3. Ramiro S, Gaujoux-Viala C, Nam JL, et al. Safety of synthetic and biological DMARDs: A systematic literature review Informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 2014;73:529-35.
4. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 2012;64:625-39.
5. Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: A network meta-analysis and Cochrane overview. Cochrane Database of Systematic Reviews 2011;33:CD008794.
6. Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The ambition study. Ann Rheum Dis 2010;69:88-96.
7. Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (option study): A double-blind, placebo-controlled, randomised trial. The Lancet 2008;371:987-97.
8. Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: Results from a 24-week multicentre randomised placebocontrolled trial. Ann Rheum Dis 2008;67:1516-23.
9. Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy Study. Arthritis Rheum 2008;58:2968-80.
10. Yun H, Xie F, Delzell E, et al. Comparative risk of hospitalized infection associated with biologic agents in rheumatoid arthritis patients enrolled in Medicare. Arthritis Rheumatol 2016;68:56-66.
11. Sakai R, Cho S-K, Nanki T, et al. Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (rA) in clinical practice: Results from the registry of Japanese RA patients on biologics for long-term safety (real) registry. Arthritis Res Ther 2015;17:74.
12. Rutherford AI, Subesinghe S, Hyrich KL, et al. Serious infection across biologictreated patients with rheumatoid arthritis: Results from the british Society for rheumatology biologics register for rheumatoid arthritis. Ann Rheum Dis 2018;77:905-10.
13. Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol 2007;5:1424-9.
14. Quek RGW, Fox KM, Wang L, et al. A US Claims-Based analysis of real-world lipidlowering treatment patterns in patients with high cardiovascular disease risk or a previous coronary event. Am J Cardiol 2016;117:495-500.
15. Desai RJ, Rao JK, Hansen RA, et al. Tumor necrosis factor-α inhibitor treatment and the risk of incident cardiovascular events in patients with early rheumatoid arthritis: A nested case-control study. J Rheumatol 2014;41:2129-36.
16. Hennessy S, Freeman C. Cunningham F: US Government Claims Databases. In: Strom B, Kimmel S, Hennessy S, et al, eds. Pharmacoepidemiology. 5th edn., 2012: 209-23.
17. Kim SY, Servi A, Polinski JM, et al. Validation of rheumatoid arthritis diagnoses in health care utilization data. Arthritis Res Ther 2011;13:R32.
18. Schneeweiss S, Robicsek A, Scranton R, et al. Veteran's Affairs hospital discharge databases coded serious bacterial infections accurately. Journal of Clinical Epidemiology 2007;60:397-409.
19. Winthrop KL, Baddley JW, Chen L, et al. Association between the initiation of Anti- Tumor necrosis factor therapy and the risk of herpes zoster. JAMA 2013;309:887-95.
20. Barber C, Lacaille D, Fortin PR. Systematic review of validation studies of the use of administrative data to identify serious infections. Arthritis Care & Research 2013;65:1343-57.
21. Gagne JJ, Glynn RJ, Avorn J, et al. A combined comorbidity score predicted mortality in elderly patients better than existing scores. Journal of Clinical Epidemiology 2011;64:749-59.
22. Ting G, Schneeweiss S, Scranton R, et al. Development of a health care utilisation data-based index for rheumatoid arthritis severity: A preliminary study. Arthritis Res Ther 2008;10:R95.
23. Schneeweiss S, Rassen JA, Glynn RJ, et al. Supplementing claims data with outpatient laboratory test results to improve confounding adjustment in effectiveness studies of lipid-lowering treatments. BMC Medical Research Methodology 2012;12:180.
24. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997;127:757-63.
25. Rassen JA, Shelat AA, Myers J, et al. One-to-many propensity score matching in cohort studies. Pharmacoepidemiology and Drug Safety 2012;21(Suppl 2):69-80.
26. Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharmaceutical Statistics 2011;10:150-61.
27. Cummings P, McKnight B, Weiss NS. Matched-pair cohort methods in traffic crash research. Accident Analysis & Prevention 2003;35:131-41.
28. Walker AM, Jick H, Hunter JR, et al. Rothman KJ: Vasectomy and non-fatal myocardial infarction. Lancet 1981;1:13-15.
29. Wang SV, Verpillat P, Rassen JA, et al. Transparency and reproducibility of observational cohort studies using large healthcare databases. Clin. Pharmacol. Ther. 2016;99:325-32.
30. Kim SC, Solomon DH, Rogers JR, et al. Cardiovascular safety of tocilizumab versus tumor necrosis factor inhibitors in patients with rheumatoid arthritis: A Multi-Database cohort study. Arthritis & Rheumatology 2017;69:1154-64.
31. Franklin JM, Rassen JA, Ackermann D, et al. Metrics for covariate balance in cohort studies of causal effects. Statistics in Medicine 2014;33:1685-99.
32. Yamamoto K, Goto H, Hirao K, et al. Long-term safety of tocilizumab: Results from 3 years of followup postmarketing surveillance of 5573 patients with rheumatoid arthritis in Japan. The Journal of Rheumatology 2015;42:1368-75.
33. Grijalva CG, Chen L, Delzell E, et al. Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 2011;306:2331-9.
34. Schneeweiss S, Setoguchi S, Weinblatt ME, et al. Anti-tumor necrosis factor α therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum 2007;56:1754-64.
35. Zink A, Manger B, Kaufmann J, et al. Evaluation of the rabbit risk score for serious infections. Annals of the Rheumatic Diseases 2014;73:1673-6.
36. Galloway JB, Hyrich KL, Mercer LK, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: Updated results from the british Society for rheumatology biologics register with special emphasis on risks in the elderly. Rheumatology 2011;50:124-31.
37. Ray WA. Evaluating medication effects outside of clinical trials: New-User designs. American Journal of Epidemiology 2003;158:915-20.
38. Yoshida K, Solomon DH, Kim SC. Active-comparator design and new-user design in observational studies. Nat Rev Rheumatol 2015;11:437-41.